Medrad has developed a second-generation injector of MR contrast media. The new product, called Spectris Solaris, will be available worldwide by March. It features enhancements that provide added control and versatility, according to the company. Solaris
Medrad has developed a second-generation injector of MR contrast media. The new product, called Spectris Solaris, will be available worldwide by March. It features enhancements that provide added control and versatility, according to the company. Solaris is compatible with MR scanners ranging from 0.2T to 2T. The company introduced its first-generation Solaris in 1996.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.